Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.46 USD

37.46
3,806,729

+0.65 (1.77%)

Updated Aug 5, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales

by Zacks Equity Research

Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.

    Zacks Equity Research

    Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss

    by Zacks Equity Research

    Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.

      Zacks Equity Research

      Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View

      by Zacks Equity Research

      Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.

        Zacks Equity Research

        Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat

        by Zacks Equity Research

        Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.

          Zacks Equity Research

          Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y

          by Zacks Equity Research

          Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.

            Zacks Equity Research

            Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

            by Zacks Equity Research

            Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

              Zacks Equity Research

              What's in the Offing for Exelixis (EXEL) in Q3 Earnings?

              by Zacks Equity Research

              Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.

                Zacks Equity Research

                Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

                by Zacks Equity Research

                Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

                  by Arpita Dutt

                  Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

                    Zacks Equity Research

                    Company News For Oct 17, 2017

                    by Zacks Equity Research

                    Companies in the news are: EXEL,TSLA,SONC,BMI

                      Zacks Equity Research

                      FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

                      by Zacks Equity Research

                      Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

                        Zacks Equity Research

                        Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session

                        by Zacks Equity Research

                        Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.

                          Zacks Equity Research

                          Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?

                          by Zacks Equity Research

                          Exelixis (EXEL) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                            Zacks Equity Research

                            Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

                            by Zacks Equity Research

                            Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.

                              Zacks Equity Research

                              Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass

                              by Zacks Equity Research

                              Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year.

                                Zacks Equity Research

                                Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag

                                by Zacks Equity Research

                                Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.

                                  Zacks Equity Research

                                  AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2

                                  by Zacks Equity Research

                                  AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.

                                    Zacks Equity Research

                                    Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates

                                    by Zacks Equity Research

                                    Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.

                                      Zacks Equity Research

                                      Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales

                                      by Zacks Equity Research

                                      Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.

                                        Zacks Equity Research

                                        Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss

                                        by Zacks Equity Research

                                        Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.

                                          Zacks Equity Research

                                          Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised

                                          by Zacks Equity Research

                                          Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.

                                            Zacks Equity Research

                                            Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2

                                            by Zacks Equity Research

                                            Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.

                                              Zacks Equity Research

                                              ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up

                                              by Zacks Equity Research

                                              ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.

                                                Zacks Equity Research

                                                Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

                                                by Zacks Equity Research

                                                Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

                                                  Zacks Equity Research

                                                  Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line

                                                  by Zacks Equity Research

                                                  Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.